Title: The effect of neoadjuvant chemoradiation therapy in resectable pancreatic cancer was
independent of intratumoral vascularization
Version: 2 Date: 26 Feb 2025
Reviewer's report:
Thank you for giving me the invaluable opportunity to review this manuscript. The authors
reported a retrospective study assessing the effect of neoadjuvant chemoradiation therapy in
resectable pancreatic cancer and its relationship with Intratumoral vascularity by contrast-
enhanced harmonic EUS.
The authors still need the following major revisions:
1. (Page 12-13 Line 49-55)
Resectable PC was defined as follows: 1) a tumor without extension into the superior mesenteric
artery, celiac artery or common hepatic artery; 2) a tumor with an abutment/encasement or a
short segment of occlusion into the superior mesenteric vein (SMV) and portal vein (PV); or 3) a
tumor that achieved downstaging after neoadjuvant chemotherapy from T4 to the above criteria.
We need more explanation on the definition of resectable pancreatic cancer, why the criteria
in this paper were different from resectability status in NCCN guideline? criterion 2) should
be considered as borderline resectable, and criterion 3) the inclusion of induced resectable
pancreatic cancer could be misleading, the authors need to clarify the rationale.
2. (Page 16-17 Line 89-94)
All patients were treated preoperatively with chemoradiation therapy. For systemic
chemotherapy, gemcitabine (1000 mg/m2) monotherapy was administered to 41 patients on days
1, 8, and 15 of each 28-day cycle. S-1 (120 mg/d) monotherapy was administered to 5 patients
for 4 weeks at 2-week intervals. Two patients were administered a combination of gemcitabine
(1000 mg/m2) and nab-PTX (125 mg/m2). Three-dimensional radiation was delivered at a total
radiation dose of 50 Gy in daily fractions of 2 Gy, 5 times per week.
The authors need to provide more specific details on chemoradiation therapy. How many cycles
of chemotherapy? What duration of radiotherapy did these patients receive before the surgical
resection?
3. Page 23 Line 157 and Page 25 Line 178
The final question, we didn’t see the Table 1 and Table 2 in the manuscript, the authors need
to add them in the next revised version.
Title: The effect of neoadjuvant chemoradiation therapy in resectable pancreatic cancer was
independent of intratumoral vascularization
Version: 2 Date: 26 Feb 2025
Reviewer's report:
Thank you for giving me the invaluable opportunity to review this manuscript. The authors
reported a retrospective study assessing the effect of neoadjuvant chemoradiation therapy in
resectable pancreatic cancer and its relationship with Intratumoral vascularity by contrast-
enhanced harmonic EUS.
The authors still need the following major revisions:
1. (Page 12-13 Line 49-55)
Resectable PC was defined as follows: 1) a tumor without extension into the superior mesenteric
artery, celiac artery or common hepatic artery; 2) a tumor with an abutment/encasement or a
short segment of occlusion into the superior mesenteric vein (SMV) and portal vein (PV); or 3) a
tumor that achieved downstaging after neoadjuvant chemotherapy from T4 to the above criteria.
We need more explanation on the definition of resectable pancreatic cancer, why the criteria
in this paper were different from resectability status in NCCN guideline? criterion 2) should
be considered as borderline resectable, and criterion 3) the inclusion of induced resectable
pancreatic cancer could be misleading, the authors need to clarify the rationale.
2. (Page 16-17 Line 89-94)
All patients were treated preoperatively with chemoradiation therapy. For systemic
chemotherapy, gemcitabine (1000 mg/m2) monotherapy was administered to 41 patients on days
1, 8, and 15 of each 28-day cycle. S-1 (120 mg/d) monotherapy was administered to 5 patients
for 4 weeks at 2-week intervals. Two patients were administered a combination of gemcitabine
(1000 mg/m2) and nab-PTX (125 mg/m2). Three-dimensional radiation was delivered at a total
radiation dose of 50 Gy in daily fractions of 2 Gy, 5 times per week.
The authors need to provide more specific details on chemoradiation therapy. How many cycles
of chemotherapy? What duration of radiotherapy did these patients receive before the surgical
resection?
3. Page 23 Line 157 and Page 25 Line 178
The final question, we didn’t see the Table 1 and Table 2 in the manuscript, the authors need
to add them in the next revised version.
Please review this paper.
user
Title: The effect of neoadjuvant chemoradiation therapy in resectable pancreatic cancer was
independent of intratumoral vascularization
Version: 2 Date: 26 Feb 2025
Reviewer's report:
Thank you for giving me the invaluable opportunity to review this manuscript. The authors
reported a retrospective study assessing the effect of neoadjuvant chemoradiation therapy in
resectable pancreatic cancer and its relationship with Intratumoral vascularity by contrast-
enhanced harmonic EUS.
The authors still need the following major revisions:
1. (Page 12-13 Line 49-55)
Resectable PC was defined as follows: 1) a tumor without extension into the superior mesenteric
artery, celiac artery or common hepatic artery; 2) a tumor with an abutment/encasement or a
short segment of occlusion into the superior mesenteric vein (SMV) and portal vein (PV); or 3) a
tumor that achieved downstaging after neoadjuvant chemotherapy from T4 to the above criteria.
We need more explanation on the definition of resectable pancreatic cancer, why the criteria
in this paper were different from resectability status in NCCN guideline? criterion 2) should
be considered as borderline resectable, and criterion 3) the inclusion of induced resectable
pancreatic cancer could be misleading, the authors need to clarify the rationale.
2. (Page 16-17 Line 89-94)
All patients were treated preoperatively with chemoradiation therapy. For systemic
chemotherapy, gemcitabine (1000 mg/m2) monotherapy was administered to 41 patients on days
1, 8, and 15 of each 28-day cycle. S-1 (120 mg/d) monotherapy was administered to 5 patients
for 4 weeks at 2-week intervals. Two patients were administered a combination of gemcitabine
(1000 mg/m2) and nab-PTX (125 mg/m2). Three-dimensional radiation was delivered at a total
radiation dose of 50 Gy in daily fractions of 2 Gy, 5 times per week.
The authors need to provide more specific details on chemoradiation therapy. How many cycles
of chemotherapy? What duration of radiotherapy did these patients receive before the surgical
resection?
3. Page 23 Line 157 and Page 25 Line 178
The final question, we didn’t see the Table 1 and Table 2 in the manuscript, the authors need
to add them in the next revised version.
assistant